Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
6.19
-0.54 (-8.02%)
At close: Mar 28, 2025, 4:00 PM
6.53
+0.34 (5.57%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Verastem Employees
As of December 31, 2024, Verastem had 80 total employees, including 78 full-time and 2 part-time employees. The number of employees increased by 3 or 3.90% compared to the previous year.
Employees
80
Change (1Y)
3
Growth (1Y)
3.90%
Revenue / Employee
$125,000
Profits / Employee
-$1,632,963
Market Cap
318.70M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VSTM News
- 5 days ago - Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire
- 10 days ago - Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Business Wire
- 5 weeks ago - Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - Business Wire
- 2 months ago - Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Business Wire
- 2 months ago - Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 2 months ago - Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - Business Wire
- 2 months ago - Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
- 2 months ago - Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - Business Wire